Last reviewed · How we verify
Ofatumumab 100
At a glance
| Generic name | Ofatumumab 100 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Characterizing the Use of Ofatumumab in a Real World Setting
- Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide (PHASE1, PHASE2)
- B Cells in Idiopathic Nephrotic Syndrome (NA)
- A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) (PHASE3)
- A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 (PHASE3)
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (PHASE1)
- Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome (PHASE2)
- Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ofatumumab 100 CI brief — competitive landscape report
- Ofatumumab 100 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI